Current Medical Research and Opinion ›

Volume 25, 2009 - Issue 7

Original Article

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

Pierre Emmanuel Paradis, Dominick Latrémouille-Viau, Yuliya Moore, Natalia Mishagina, Marie-Hélène Lafeuille, Patrick Lefebvre, ...show all

Pages 1793-1805 | Accepted 15 May 2009, Published online: 05 Jun 2009

Cite this article https://doi.org/10.1185/03007990903044374

ABSTRACT

Objectives: To explore the effects of generic substitution of the antiepileptic drug (AED) topiramate (Topamax in Canada; to convert observed Canadian costs into the settings of France, Germany, Italy, and the United Kingdom (UK); and to forecast the economic impact of generic topiramate entry in these four European countries.

† Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

Research design and methods: Health claims from Régie de l'assurance maladie du Québec (RAMQ) plan (1/2006–9/2008) and IMS Health data (1998–2008) were used.

Patients with epilepsy and ≥2 topiramate dispensings were selected. An open-cohort design was used to classify observation into mutually-exclusive periods of branded versus generic use of topiramate. Canadian healthcare utilization and costs (2007 CAN$/person-year) were compared between periods using multivariate models. Annualized per-patient costs (2007€ or 2007£/person-year) were converted using Canadian utilization rates, European prices and service-use ratios. Non-parametric bootstrap served to assess statistical significance of cost differences. Topiramate market was forecasted following generic entry (09/2009–09/2010) using autoregressive models based on the European experience. The economic impact of generic topiramate entry was estimated for each country.

Results: A total of 1164 patients (mean age: 39.8 years, 61.7% female) were observed for 2.6 years on average. After covariates adjustment, generic-use periods were associated with increased pharmacy dispensings (other AEDs: +0.95/person-year, non-AEDs: +12.28/person-year, $p < 0.001$), hospitalizations (+ 0.08/person-year, $p = 0.015$), and lengths of hospital stays (+0.51 days/person-year, $p < 0.001$). Adjusted costs, excluding topiramate, were CAN$1060/person-year higher during generic use ($p = 0.005$). Converted per-patient costs excluding topiramate were significantly higher for generic relative to brand periods in all European countries (adjusted cost differences per person-year: €706–815, $p < 0.001$ for all comparisons). System-wide costs would increase from 3.5 to 24.4% one year after generic entry.

Limitations: Study limitations include the absence of indirect costs, possible claim inaccuracies, and IMS data limitations.

Conclusions: Higher health costs were projected for G4 European countries from the Canadian experience following the generic entry of topiramate.

Key words: :

Antiepileptic drugs | Budget impact | Cost conversion | Generic substitution

Transparency

Declaration of funding

This analysis was sponsored by Janssen-Cilag EMEA, a division of Janssen Pharmaceutica NV.

Declaration of financial/other relationships

M.G. has disclosed that she is an employee of Janssen-Cilag EMEA. All other co-authors disclosed that they are employees of Analysis Group, Inc., which has received research grants to conduct this study from Janssen-Cilag EMEA.

All peer reviewers receive honoraria from CMRO for their review work. Peer reviewer 1 disclosed that he/she has received grant support from GlaxoSmithKline. Peer reviewer 2 disclosed that he/she has no relevant financial relationships.

Acknowledgment

Janssen-Cilag EMEA participated in the design, review, and approval of the manuscript.

The authors disclosed no further assistance in preparation of this manuscript.

Notes

† Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

*Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

Related Research Data

Topiramate
Source: Drugs
Estimation of Epileptic Foci Using the Dipole Tracing Method in Epileptic Seizures with Structural Lesions of the Brain
Source: Journal of Epilepsy
Off-patent drugs in Italy

Source: The European Journal of Health Economics

Moving Towards more Sustainable Healthcare Financing in Germany

Source: Unknown Repository

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting

Source: Current Medical Research and Opinion

Are there potential problems with generic substitution of antiepileptic drugs?

Source: Seizure

Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to

Related research

People also read | Recommended articles | Cited by 11